

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87757

Toshiyuki TAKASU, et al.

Appln. No.: 10/534,290

Group Art Unit: 1614

Confirmation No.: 9818

Examiner: Charlesworth E. RAE

Filed: May 9, 2005

For: REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE
DERIVATIVE AS THE ACTIVE INGREDIENT

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby
notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached
PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem
material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following:
U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications
filed after June 30, 2003.

The present Information Disclosure Statement is being filed (without a Statement Under
37 C.F.R. § 1.97(c)) after the later of three months from the application's filing date and the

mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore the statutory fee of \$180.00 under 37 C.F.R. § 1.17(p) is being charged to Deposit Account No. 19-4880 via EFS Payment Screen. The USPTO is also directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3)(i) for foreign language documents, Applicant encloses herewith a copy of a Communication from the Patent Office of the State Intellectual Property Office of the People's Republic of China in a counterpart application citing such documents together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the Chinese patent office.

In addition, Applicant encloses herewith, an English-language abstract of GUO-MING ZHAO, et al., "Advance on the Research on and Development of β_3 -Adrenoceptor Agonists", Chinese Jurnal of Medicinal Chemistry, June 2001, Pages 177-181, Vol. 11, No. 3, China Academic Journal Electronic Publishing House.

In compliance with 37 C.F.R. § 1.98(a)(2)(ii), Applicant encloses herewith a copy of a Communication from the European Patent Office in a counterpart application citing such documents.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/534,290

Attorney Docket No.: Q87757

waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

/Tu A. Phan/

Tu A. Phan, Ph.D.
Registration No. 59,392

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: June 12, 2007